We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Debra Times Seven for Sanofi-Aventis ADME Research

Debra Times Seven for Sanofi-Aventis ADME Research

Debra Times Seven for Sanofi-Aventis ADME Research

Debra Times Seven for Sanofi-Aventis ADME Research

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Debra Times Seven for Sanofi-Aventis ADME Research"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sanofi-Aventis has adopted LabLogic's Debra LIMS for non-clinical ADME studies across all seven of its R&D locations in Europe and North America.

The company is running the latest release of Debra (5.6.3) on a Citrix server in its Global Metabolism & Pharmacokinetic Department in Montpellier, with connections to Chilly-Mazarin, Alfortville, Frankfurt, Budapest and Bridgewater USA.

It has taken three years to implement the programme, beginning in 2004 with the decision to centralize and the choice of Debra as the LIMS best suited to meeting the needs of the different sites. User requirement specifications were drawn up in 2005 for development by LabLogic the following year. The system was validated in the first half of 2007 in time for implementation in June.

The harmonization resolves inconsistencies in LIMS practices following the Sanofi-Synthelabo / Aventis merger, as a result of which some sites had more experience of Debra than others and two were using different systems entirely.

"We anticipate that standardizing on Debra will reduce costs and help us to follow the same studies procedures at all our sites, but the biggest advantage is likely to be the sharing of data," said Valerie Gall of the Montpellier GMPK.

"With all our ADME compound information on a single database we will be able to compare studies from different sites quickly and easily."